IDEAYA Biosciences (IDYA) Cash from Financing Activities (2018 - 2026)

IDEAYA Biosciences (IDYA) has 9 years of Cash from Financing Activities data on file, last reported at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 95.48% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (down 98.64% YoY), and the FY2025 full-year result was $29.8 million, down 95.6% from the prior year.
• Cash from Financing Activities declined to $1.2 million in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $349.1 million in Q1 2024 to a low of $301000.0 in Q3 2025.
• A 5-year average of $68.7 million and a median of $2.9 million in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities soared 43385.8% in 2023 and slumped 99.89% in 2025, its largest moves.
• Tracing IDYA's Cash from Financing Activities over 5 years: stood at $324000.0 in 2022, then soared by 43385.8% to $140.9 million in 2023, then slumped by 98.05% to $2.8 million in 2024, then fell by 22.63% to $2.1 million in 2025, then sank by 44.55% to $1.2 million in 2026.
• Business Quant data shows IDYA's Cash from Financing Activities at $1.2 million in Q1 2026, $2.1 million in Q4 2025, and $301000.0 in Q3 2025.